Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma

Gu W, Gan J, Liu P, Lai J, Liu C, Zhang G, Shi C, Jiang Q, Qiu F

Drug Design, Development and Therapy 2025, 19:11411-11431

Published Date: 20 December 2025